Circulating RANKL/OPG in polymyalgia rheumatica

Lia Pulsatelli, Paolo Dolzani, Tania Silvestri, Luigi Boiardi, Carlo Salvarani, Pierluigi Macchioni, Andrea Facchini, Riccardo Meliconi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objective. To evaluate whether RAN-KL/OPG balance is modified in PMR patients, either in the active phase of the disease or during corticosteroid treatment. Methods. Circulating levels of RANKL and OPG were assayed by enzyme-linked immunosorbent assay in PMR patients with active untreated disease and in patients treated by corticosteroids over a 12-month follow-up period. Results. We found no statistically significant differences in circulating levels of OPG between PMR patients either in the active phase of the disease or during all follow-up period compared to normal controls. On the other hand, systemic production of sRANKL is increased and is not modulated by corticosteroid treatment. Conclusions. In PMR increased levels of sRANKL may be related to bone osteoporosis. Further investigations are necessary to evaluate the relationship between the RANK/RANKL/OPG system and bone turnover in PMR patients.

Original languageEnglish
Pages (from-to)621-623
Number of pages3
JournalClinical and Experimental Rheumatology
Volume25
Issue number4
Publication statusPublished - Jul 2007

Fingerprint

Polymyalgia Rheumatica
Adrenal Cortex Hormones
Bone Remodeling
Osteoporosis
Enzyme-Linked Immunosorbent Assay
Bone and Bones
Therapeutics

Keywords

  • Osteoprotegerin
  • Polymyalgia rheumatica
  • RANKL

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

Circulating RANKL/OPG in polymyalgia rheumatica. / Pulsatelli, Lia; Dolzani, Paolo; Silvestri, Tania; Boiardi, Luigi; Salvarani, Carlo; Macchioni, Pierluigi; Facchini, Andrea; Meliconi, Riccardo.

In: Clinical and Experimental Rheumatology, Vol. 25, No. 4, 07.2007, p. 621-623.

Research output: Contribution to journalArticle

Pulsatelli, L, Dolzani, P, Silvestri, T, Boiardi, L, Salvarani, C, Macchioni, P, Facchini, A & Meliconi, R 2007, 'Circulating RANKL/OPG in polymyalgia rheumatica', Clinical and Experimental Rheumatology, vol. 25, no. 4, pp. 621-623.
Pulsatelli, Lia ; Dolzani, Paolo ; Silvestri, Tania ; Boiardi, Luigi ; Salvarani, Carlo ; Macchioni, Pierluigi ; Facchini, Andrea ; Meliconi, Riccardo. / Circulating RANKL/OPG in polymyalgia rheumatica. In: Clinical and Experimental Rheumatology. 2007 ; Vol. 25, No. 4. pp. 621-623.
@article{f3bd9c7a3dc94dc9a8eea4bf45619ba4,
title = "Circulating RANKL/OPG in polymyalgia rheumatica",
abstract = "Objective. To evaluate whether RAN-KL/OPG balance is modified in PMR patients, either in the active phase of the disease or during corticosteroid treatment. Methods. Circulating levels of RANKL and OPG were assayed by enzyme-linked immunosorbent assay in PMR patients with active untreated disease and in patients treated by corticosteroids over a 12-month follow-up period. Results. We found no statistically significant differences in circulating levels of OPG between PMR patients either in the active phase of the disease or during all follow-up period compared to normal controls. On the other hand, systemic production of sRANKL is increased and is not modulated by corticosteroid treatment. Conclusions. In PMR increased levels of sRANKL may be related to bone osteoporosis. Further investigations are necessary to evaluate the relationship between the RANK/RANKL/OPG system and bone turnover in PMR patients.",
keywords = "Osteoprotegerin, Polymyalgia rheumatica, RANKL",
author = "Lia Pulsatelli and Paolo Dolzani and Tania Silvestri and Luigi Boiardi and Carlo Salvarani and Pierluigi Macchioni and Andrea Facchini and Riccardo Meliconi",
year = "2007",
month = "7",
language = "English",
volume = "25",
pages = "621--623",
journal = "Clinical and Experimental Rheumatology",
issn = "0392-856X",
publisher = "Clinical and Experimental Rheumatology S.A.S.",
number = "4",

}

TY - JOUR

T1 - Circulating RANKL/OPG in polymyalgia rheumatica

AU - Pulsatelli, Lia

AU - Dolzani, Paolo

AU - Silvestri, Tania

AU - Boiardi, Luigi

AU - Salvarani, Carlo

AU - Macchioni, Pierluigi

AU - Facchini, Andrea

AU - Meliconi, Riccardo

PY - 2007/7

Y1 - 2007/7

N2 - Objective. To evaluate whether RAN-KL/OPG balance is modified in PMR patients, either in the active phase of the disease or during corticosteroid treatment. Methods. Circulating levels of RANKL and OPG were assayed by enzyme-linked immunosorbent assay in PMR patients with active untreated disease and in patients treated by corticosteroids over a 12-month follow-up period. Results. We found no statistically significant differences in circulating levels of OPG between PMR patients either in the active phase of the disease or during all follow-up period compared to normal controls. On the other hand, systemic production of sRANKL is increased and is not modulated by corticosteroid treatment. Conclusions. In PMR increased levels of sRANKL may be related to bone osteoporosis. Further investigations are necessary to evaluate the relationship between the RANK/RANKL/OPG system and bone turnover in PMR patients.

AB - Objective. To evaluate whether RAN-KL/OPG balance is modified in PMR patients, either in the active phase of the disease or during corticosteroid treatment. Methods. Circulating levels of RANKL and OPG were assayed by enzyme-linked immunosorbent assay in PMR patients with active untreated disease and in patients treated by corticosteroids over a 12-month follow-up period. Results. We found no statistically significant differences in circulating levels of OPG between PMR patients either in the active phase of the disease or during all follow-up period compared to normal controls. On the other hand, systemic production of sRANKL is increased and is not modulated by corticosteroid treatment. Conclusions. In PMR increased levels of sRANKL may be related to bone osteoporosis. Further investigations are necessary to evaluate the relationship between the RANK/RANKL/OPG system and bone turnover in PMR patients.

KW - Osteoprotegerin

KW - Polymyalgia rheumatica

KW - RANKL

UR - http://www.scopus.com/inward/record.url?scp=34648834438&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34648834438&partnerID=8YFLogxK

M3 - Article

VL - 25

SP - 621

EP - 623

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

SN - 0392-856X

IS - 4

ER -